Executive Profiles

Ahead of today's announcement of the winning entry, Mark Reisenauer, senior vice president, Oncology Business Unit at Astellas, tells PharmExec about the development and objectives of the Astellas Oncology C3 Prize.

Pharm Exec speaks to Prognos CEO Sundeep Bhan about how the company’s unique offering will reach beyond life sciences as the long-promised benefits of AI become reality.

This article explores the difficult nature of developing drugs for rare diseases and discusses what a pharmaceutical executive can actively do to help increase success.

Pharm Exec’s 10th annual list of rising leaders highlights 11 pharma managers who are poised to help chart the industry’s path forward.

Ed Gudaitis Allergan VP and Country Manager, Canada, explains how embracing disruption is his secret to success.

Selecta Biosciences CEO Dr. Werner Cautreels talks about the company's innovative technology and how his entrepreneurial experiences in big pharma prepared him for the challenge of a new startup.

Mary Lynne Hedley, president and COO of TESARO, talks to Pharm Exec about the company’s innovative approach to responsible drug development and commercialization, and how its theory of putting patients first is translated into practise.

Former critical care nurse Cynthia Schwalm, now executive vice president and president of North American commercial operations for Ipsen, speaks with Pharm Exec about her formula for successful team building internally-and the importance today of stepping outside of the C-suite and into the world of the patient.

Dr. Fumie Griego, the International Federation of Pharmaceutical Manufacturers and Associations’ new Assistant Director General, speaks with Pharm Exec about her mission to use IFPMA ’s international reach to find real and practical solutions to the most pressing global healthcare challenges.

Everyone’s talking value, but not everyone is willing to pin down the elusive concept. Pharm Exec talks with Steven Pearson, founder of the Institute for Clinical Effectiveness Review (ICER), about all things value-based.

Justin Zamirowski, Edge Therapeutic’s Senior Director of Operational Excellence, and Andy Mehrotra, CEO of Boston-based cloud software developer EightSpokes, discuss how a new, collaborative approach to managing projects across the enterprise is improving time to market.

Females students pursuing a Science, Technology, Engineering, and Mathematics (STEM) pathway need earlier enticement and more C-suite role models, writes Mylan’s EVP & Chief Strategy Officer, Adele Gulfo.

Q&A spotlights the development of one injection device that is helping change the treatment-adherence landscape.

A panel of biopharma executives discuss market access and the changing dynamics in reaching physicians and healthcare professionals.

Multi-channel marketing manager Adi Borovick discusses the implications of compliance for marketers in a world where new technologies being created every day.

At recent the BETHEEXPERT 2017 event in Budapest, we asked Romuald Braun what pharma should be focusing on with regard to its labeling activities.

Pharm Exec speaks to Andrew Marr about the implications of the European Union's new IDMP (Identification of Medicinal Products) regulations for the pharma industry.

The digital workplace is defined as a “business strategy to boost employee engagement and agility through a more consumerized work environment”. But what exactly does this mean for life sciences organizations? Michael Woodbridge explains.

New DTC campaign for its vaccine Zostavax uses a more serious, personal messaging approach-as pharmas look to close the conversation gaps between patients and healthcare providers.

For Bahija Jallal, chosen this year's Healthcare Businesswomen’s Association Woman of the Year, a passion for translational science has been the central guide in a career rise from cancer researcher to leading a big pharma biotech engine.

Six years in, Pharm Exec looks at the progress of the International Rare Diseases Research Consortium-an ambitious global effort focused on accelerating orphan disease diagnosis, and ultimately enabling better treatment options for these underserved patient populations.

A conversation with Tommy Fanning, head of biopharma at IDA Ireland, about the country’s growth as a manufacturing powerhouse-and its bid to attract UK-based EMA post-Brexit.

Pharm Exec talks to Hugo Fry, Sanofi’s General Manager for the UK and General Manager for Sanofi Pasteur UK and Ireland, about his vision for the company and the vaccine space in these markets.

Pharm Exec speaks to Chris Molloy, CEO of the newly established Medicines Discovery Catapult, which aims to establish new approaches to grow and sustain the UK's reputation for innovative, fast-to-patient drug discovery.

Pharm Exec talks to Mel Formica, Takeda’s Vice President of Global Market Access, about what he sees as the challenges and opportunities in 2017, and how he envisions the industries market access capabilities evolving.

Pharm Exec speaks to ICON's Ramita Tandon about how the UK and European regulators' market access plans for 2017 will affect the industry.

Pharm Exec speaks with Spanish-born Belén Garijo, CEO of Merck KGaA, Darmstadt, Germany’s healthcare business, who shares her steady-eyed approach in transforming a traditional pharma unit focused on small molecules for chronic disease to a high-tech specialty producer of immunotherapy drugs for rare cancers.

Anthony Arnold offers an overview and update of bioelectronic medicine.

Pharm Exec sits down with veteran journalist Paula Apsell, the driving force behind the long-running PBS science series NOVA. Apsell offers straightforward advice to the biopharma industry: make your business a business of inspiration, where the return is measured in passion-and the sheer, simple pleasure of finding things out.

The FDA’s Dr. John Whyte offers his perspectives on patient centricity and the issues that FDA and industry are facing.